Compare · SIBN vs SYK
SIBN vs SYK
Side-by-side comparison of SI-BONE Inc. (SIBN) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SIBN and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 126.0x SIBN ($892.3M).
- Over the past year, SIBN is up 29.4% and SYK is down 22.8% - SIBN leads by 52.2 points.
- SYK has been more active in the news (7 items in the past 4 weeks vs 6 for SIBN).
- SYK has more recent analyst coverage (25 ratings vs 12 for SIBN).
- Company
- SI-BONE Inc.
- Stryker Corporation
- Price
- $19.68-1.18%
- $294.69+0.46%
- Market cap
- $892.3M
- $112.48B
- 1M return
- +8.82%
- +5.16%
- 1Y return
- +29.40%
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 6
- 7
- Recent ratings
- 12
- 25
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest SIBN
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 144 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SEC Form 4 filed by SI-BONE Inc.
- SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Director Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $378,160 worth of shares (20,000 units at $18.91) as part of a pre-agreed trading plan (SEC Form 4)
- SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
- Chief Executive Officer Francis Laura sold $522,596 worth of shares (25,972 units at $20.12) as part of a pre-agreed trading plan (SEC Form 4)
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)